Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TRS01 eye drops
TRS01 eye · 2 trials · 2 indications
Number of patients experiencing Adverse Events during the study
| Arm | Type | Description |
|---|---|---|
| TRS01 low dose | EXPERIMENTAL | - |
| TRS01 high dose | EXPERIMENTAL | - |
| TRS01 medium dose | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TRS01 eye drops | DRUG | Dosed four times a day (QID) |
| Placebo eye drops | DRUG | Dosed QID |
Inclusion Criteria: * 18 years of age or older * Able to provide informed consent, follow instructions and complete all required study visits for the duration of the study. * Diagnosed with active non-infectious anterior uveitis requiring an increase or initiation of topical steroids for management...
TRS01 eye is an investigational small molecule being studied for two eye conditions: non-infectious anterior uveitis and post-surgical ocular inflammation. Both are inflammatory conditions of the eye. It is being developed by Tarsier Pharma Ltd. and has been tested in Phase 1 clinical trials in the United States.
TRS01 eye drops are being developed by Tarsier Pharma Ltd., which trades under the ticker TARX. The company is advancing the small molecule as a topical ophthalmology candidate for inflammatory eye conditions, including non-infectious anterior uveitis and post-surgical ocular inflammation.
TRS01 eye is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. Two completed Phase 1 trials have evaluated the drug, one in post-surgical ocular inflammation and one in active non-infectious anterior uveitis, both conducted in the United States.
TRS01 eye has been studied in two completed Phase 1 trials. NCT04222725 evaluated TRS01 in participants with post-surgical ocular inflammation and enrolled 37 participants. NCT04222712 evaluated TRS01 eye drops in participants with active non-infectious anterior uveitis and enrolled 16 participants. Both trials were randomized, double-blind, and controlled.
Yes, TRS01 eye and TRS01 eye drops refer to the same investigational product from Tarsier Pharma Ltd. The eye drop formulation is the topical ophthalmic form studied in the company's Phase 1 clinical trials for non-infectious anterior uveitis and post-surgical ocular inflammation.